Among the therapeutic approaches tested to inhibit the deleterious effect of TGF-β family members in fibrosis or in early stages in cancer, a natural regulator of antibodies, such as the proteoglycan decorin that can enhance or inhibit the activity of TGF-β1, or chimeric proteins TGF-βRII-IgG Fc, as well as over-expression of SMAD7 or dominant negative mutant forms of receptors, have been proposed [196,263]. Here, SMAD7 is linked to cancer.